ORGANOGENESIS HOLDINGS INC. (ORGO) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 56.96M USD | Liabilities, Current |
| Cash and equivalents | 46.10M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 100.94M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 29.28M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $56.96M | $46.10M | (m) | $100.94M | $29.28M | (m) |
| 2026-03-31 | (m) | $76.02M | $91.38M | (m) | $116.91M | $28.43M | (m) |
| 2025-12-31 | (m) | $100.12M | $93.68M | (m) | $217.45M | $29.63M | (m) |
| 2025-09-30 | (m) | $90.32M | $63.74M | (m) | $168.78M | $39.58M | (m) |
| 2025-06-30 | (m) | $65.84M | $73.08M | (m) | $120.38M | $33.04M | (m) |
| 2025-03-31 | (m) | $65.05M | $109.97M | (m) | $103.32M | $29.34M | (m) |
| 2024-12-31 | (m) | $77.48M | $135.57M | (m) | $109.86M | $26.22M | (m) |
| 2024-09-30 | (m) | $77.28M | $94.34M | (m) | $101.27M | $27.04M | (m) |
| 2024-06-30 | (m) | $85.73M | $89.90M | (m) | $105.94M | $26.88M | (m) |
| 2024-03-31 | (m) | $82.80M | $88.63M | (m) | $96.15M | $27.69M | (m) |
| 2023-12-31 | (m) | $80.51M | $103.84M | (m) | $82.00M | $28.25M | (m) |
| 2023-09-30 | (m) | $81.48M | $98.23M | (m) | $89.28M | $27.91M | (m) |
| 2023-06-30 | (m) | $73.45M | $88.92M | (m) | $93.61M | $25.36M | (m) |
| 2023-03-31 | (m) | $76.08M | $88.69M | (m) | $92.02M | $25.54M | (m) |
| 2022-12-31 | (m) | $75.02M | $102.48M | (m) | $89.45M | $24.78M | (m) |
| 2022-09-30 | (m) | $89.27M | $107.25M | (m) | $93.11M | $24.68M | (m) |
| 2022-06-30 | (m) | $88.23M | $112.28M | (m) | $88.82M | $23.23M | (m) |
| 2022-03-31 | (m) | $76.79M | $107.90M | (m) | $79.48M | $22.74M | (m) |
| 2021-12-31 | (m) | $82.00M | $113.93M | (m) | $82.46M | $25.02M | (m) |
| 2021-09-30 | (m) | $81.00M | (m) | (m) | $74.58M | $29.50M | (m) |
| 2021-06-30 | (m) | $84.55M | (m) | (m) | $76.77M | $28.11M | (m) |
| 2021-03-31 | (m) | $74.01M | (m) | (m) | $72.00M | $29.72M | (m) |
| 2020-12-31 | (m) | $68.22M | (m) | (m) | $56.80M | $27.80M | (m) |
| 2020-09-30 | (m) | $66.25M | (m) | (m) | $56.91M | $29.88M | (m) |
| 2020-06-30 | (m) | $66.06M | (m) | (m) | $44.02M | $28.56M | (m) |
| 2020-03-31 | (m) | $54.83M | (m) | (m) | $32.72M | $26.44M | (m) |
| 2019-12-31 | (m) | $59.89M | (m) | (m) | $39.36M | $22.92M | (m) |
| 2019-09-30 | (m) | $56.73M | (m) | (m) | $34.38M | $20.18M | (m) |
| 2019-06-30 | (m) | $50.40M | (m) | (m) | $34.16M | $18.72M | (m) |
| 2019-03-31 | (m) | $52.31M | (m) | (m) | $32.51M | $17.97M | (m) |
| 2018-12-31 | (m) | $66.39M | (m) | (m) | $34.08M | $13.32M | (m) |
| 2018-09-30 | (m) | $8.01M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $5.90M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $5.06M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $3.93M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $2.70M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $85.83K | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $140.82K | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $478.36K | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | $852.58K | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $416.43K | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |